@ddwn I wouldn’t call it being frightened of the moment. It’s about risk management. I’ve done reasonably well holding and trading MSB this year. And yes, one has to make a deduction based on logic, available information and a gut feel. My gut feel is that the DSMB will (after the imminently 60% readout) recommend the COVID ARDS trial continue into next year. That’s my hunch, so therefore it comes down to whether I’m confident to risk 100% of my investment on a less likely positive result for CHF, or even less likely IMO a positive result for CLBP.
@semi retired Yes I do believe in my own research and my commentary to
@ddwn is my gut feel on MSB. I think you are sitting pretty with your more diversified strategy whereas I am (ironically) more of a risk taker, and probably a slow learner. Good luck.
@Tobes1234 Unfortunately MSB cannot ultimately withhold the release of the CLBP and CHF results if the independent parties have handed them to MSB. I’m sure they can fudge a few days, possibly a week under the guise of ‘assessing and interpreting’ the results or whatever, but this is treading a wafer thin legal line.
@wagster Again see my comments to
@Tobes1234 about ‘managed’ timing of the release of results to the market. At the end of the day I would be extremely happy for MSB and shareholders for a positive readout hopefully next week for whatever readout comes first. I’ll accept and willingly pay double today’s share price for example to get back in, knowing that the tech is irrefutably validated and will double again, or triple or quadruple again in subsequent years.
@Lopez Not actually true about me not having confidence in stocks I own. I am very positive on MSB, the building blocks and patents in place, the outstanding executive team, new partnerships and incredible ARDS opportunity ahead. You may be referring to my on again off again love affair with Starpharma (SPL). My favourite whipping boy. I’m pretty loud in my often dissatisfaction on Hotcopper and to investor relations. I am definitely a quizzical and sceptical investor, and I try to read between the lines and query statements from companies rather than take at face value. I think that’s wise. So if you want to call me a ‘glass half full’ investor then I’ll probably have to accept that. I’ve been holding/trading SPL for around 15 years from memory. I bought back in this week for info. This is a case study on excellent and high potential platform technology in the pharmaceutical/biotech space that overall is being butchered by poor commercialisation strategies and execution. Needs a fresh CEO and board with a demonstrated commercialisation history. But hopefully SPL will come good.
@danzae Wow that is a massive holding and solid faith in MSB. Well done on that. Each to there own but it seems lightening your holding by 20% gives a nice little bit of insurance and opportunity to top up at lower prices.
I held all my MSB (only a fraction of your investment though) through the FDA briefing notes saga, and again through the ODAC meeting and vote. Probably like you, I listened to the whole meeting throughout the night and till dawn. What a stressful but ultimately jubilant night that was. The last trading day before the negative FDA decision I deliberated hard about the best and safest personal strategy. Hold, sell half or sell all MSB prior to the decision. Each option then had a trading investment strategy to follow. It was risk/reward. My head told me to sell half. My heart based on the prior 9-1 ODAC vote as well as a bit if good old fashioned greed swayed me to hold. I like the rest of us took a big hit and I’ve had to trade well to get some decent gains back. So now on balance of expectations of upcoming results of done a 180 and gone the other way. Locking in profits and will wait and see. Positive results will no doubt be life changing for you and many others here if one or more positive results are coming. Wishing you the best.
Everyone: Whilst it’s been interesting to hear people’s opinions about their holding or trading rationales, the main thrust and intent of my original post was to ascertain what people think about the role of stem cells in chronic conditions such as CLBP. After all, the P3 trial involved only one, not multiple doses of the therapy. I think we may have a game changer in the method of action and therapeutic effect of the stem cells in Cytokine storm situations and in other acute conditions in the area of ARDS. But MSB have already acknowledged that the delivered stem cells likely only have a limited life in the body. Is it enough to trigger various mechanisms and positive actions in an acute setting? It looks promising. But do these mechanisms and actions trigger an ongoing positive action and benefit in chronic conditions such as lower back pain? I’m not so sure. I would really appreciate some opinions on this from anyone with a bit more in depth knowledge than myself.
Thanks in advance.
(20min delay)